Abstract | BACKGROUND: METHODS: This cross-sectional study was performed in 305 patients with FD from seven academic hospitals in four European countries. Information was collected from clinical records. RESULTS: Patients mean (±standard deviation) age was 60.9±14.4 years, 201 (66%) were male, 69 (23%) had diabetes mellitus (DM) and 87 (29%) had a prior history of CVD. Mean body mass index was 28.5±5.0 kg/m2. Lipid-lowering medication was used by 227 (74%) patients (27% usual dose (theoretical low-density lipoprotein cholesterol ( LDL-C) reduction≤40%) and 46% intensive dose (theoretical LDL-C reduction>40%)). Non high-density lipoprotein cholesterol (non-HDL-C) levels below treatment target (<3.3 mmol/L) were present in 123 (40%) patients and 163 patients (53%) had LDL-C levels below target (<2.5 mmol/L). No significant determinants were found for having non-HDL-C levels below target, while a prior history of CVD (OR 1.90, 95%CI 1.05-3.47) and presence of DM (OR 2.00, 95%CI 1.08-3.70) were associated with having LDL-C levels below treatment target. CONCLUSION: The majority of FD patients had non-HDL-C levels above the treatment target of 3.3 mmol/L. Intensive dose lipid-lowering medication was used by only half of the patients, leaving them at increased cardiovascular risk.
|
Authors | C Koopal, K Retterstøl, B Sjouke, G K Hovingh, E Ros, J de Graaf, R P F Dullaart, S Bertolini, F L J Visseren |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 240
Issue 1
Pg. 90-7
(May 2015)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 25768710
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Biomarkers
- Cholesterol, HDL
- Cholesterol, LDL
- Hypolipidemic Agents
|
Topics |
- Academic Medical Centers
- Aged
- Biomarkers
(blood)
- Cardiovascular Diseases
(diagnosis, epidemiology, prevention & control)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Comorbidity
- Cross-Sectional Studies
- Diabetes Mellitus
(epidemiology)
- Europe
(epidemiology)
- Female
- Humans
- Hyperlipoproteinemia Type III
(blood, diagnosis, drug therapy, epidemiology)
- Hypolipidemic Agents
(therapeutic use)
- Logistic Models
- Male
- Middle Aged
- Odds Ratio
- Prevalence
- Risk Assessment
- Risk Factors
- Treatment Outcome
|